DXS INTERNATIONAL PLC
Exercise of Warrants
The Board of DXS International Plc ("DXS" or the "Company"), the ISDX quoted developer and supplier of clinical decision support systems to Clinical Commissioning Groups, GPs, doctors and healthcare professionals, is pleased to announce that it received Notices of Exercise from current warrant holders in respect of 480,000 warrants on 30th April. Of these warrants 400,000 were exercised at 10p per ordinary share and 80,000 were exercised at 15p per ordinary share.
The Company issued 480,000 new Ordinary Shares on 30th April to the exercising warrant holders and following this issue the issued share capital of the Company is now 33,396,416 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interests in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules
The Company has not received Notices of Exercise in respect of the remaining warrants that expired on 30th April. The number of warrants outstanding is therefore reduced by a total of 360,000.
One of the exercising warrant holders, Richard Gathercole, will, after the issue of 200,000 new ordinary shares pursuant to this exercise, be beneficially interested in 1,251,667 ordinary shares representing 3.75% per cent. of the total ordinary shares in issue. The other exercising warrant holder, John Godley, will, after the issue of 280,000 new ordinary shares pursuant to this exercise, be beneficially interested in 1,196,667 ordinary shares representing 3.58% per cent. of the total ordinary shares in issue
David Immelman commented "I am delighted that these long standing shareholders have decided to exercise their warrants and continue to support the Company. "
The Directors of DXS International plc accept responsibility for this announcement
| David Immelman, CE0 || 01252 719800 |
| DXS International Plc || |
| www.dxs-systems.com || |
| || |
| Corporate Adviser || |
| City & Merchant Ltd || |
| David Papworth || 020 7101 7676 |
| || |
Notes to Editors
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DXS International plc via Globenewswire